other_material
confidence high
sentiment neutral
materiality 0.85
KALA BIO enters $6M private placement, resolves Oxford default, appoints David Lazar as CEO
KALA BIO, Inc.
- First closing raised $1.8M from 900k Series AA preferred shares at $2/share; second closing up to $4.2M subject to stockholder approval.
- Oxford loan settlement: $2M cash and 1.62M common shares reduce loan by $7M; $1M initial cash due by Jan 15, 2026 or stockholder meeting.
- David Lazar appointed CEO and board chair; Mary Reumuth terminated as CFO; Gregory Perry resigns from board.
- Company terminated all remaining employees in October after Oxford foreclosure; now resumes operations with limited cash from placement.
- Stockholder meeting required before March 31, 2026 to approve share increase and conversion of preferred shares.